États-Unis - anglais - NLM (National Library of Medicine)

eagle pharmaceuticals, inc. - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. risk summary there are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased [see dosage and administration (2.2) and see clinical pharmacology (12.3) ]. maternal adverse reactions: vasopressin injection may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the pres

États-Unis - anglais - NLM (National Library of Medicine)

eugia us llc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. risk summary there are no available data on vasopressin use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasopressin  may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injec

États-Unis - anglais - NLM (National Library of Medicine)

baxter healthcare corporation - vasopressin (unii: y4907o6mfd) (vasopressin - unii:y4907o6mfd) - vasopressin in sodium chloride injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin in sodium chloride injection is contraindicated in patients with a known allergy or hypersensitivity to 8-l-arginine vasopressin. risk summary there are no available data on vasopressin in sodium chloride injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted. clinical considerations there are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. safety and effectiveness of vasopressin in sodium chloride injection in pediatric patients with vasodilatory shock have not been established. clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see warnings and precautions (5), adverse reactions (6), and clinical pharmacology (12.3)].

Canada - anglais - Health Canada

fresenius kabi canada ltd - vasopressin - solution - 20unit - vasopressin 20unit - pituitary

Canada - anglais - Health Canada

sandoz canada incorporated - vasopressin - solution - 20unit - vasopressin 20unit - pituitary

États-Unis - anglais - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - vasopressin, unspecified (unii: y87y826h08) (vasopressin, unspecified - unii:y87y826h08) - vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. vasostrict® is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. 8.1 pregnancy pregnancy category c risk summary: there are no adequate or well-controlled studies of vasostrict® in pregnant women. it is not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. animal reproduction studies have not been conducted with vasopressin [see clinical pharmacology ( 12-12.3)]. clinical considerations: because of increased clearance of vasopressin in the second and third trimester, the dose of vasostrict® may need to be up-titrated to doses exceeding 0.1 units/minute in post-cardiotomy shock and 0.07 units/minute in septic shock. vasostrict® may produce tonic uterine contractions that could threaten the continuatio

Canada - anglais - Health Canada

ferring inc - vasopressin - liquid - 20unit - vasopressin 20unit - pituitary

Canada - anglais - Health Canada

lyphomed, division of fujisawa canada inc. - vasopressin - liquid - 20unit - vasopressin 20unit - pituitary

États-Unis - anglais - NLM (National Library of Medicine)

medical purchasing solutions, llc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. risk summary there are no available data on vasopressin use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin may need to be increased [see  dosage and administration (2.2)and clinical pharmacology (12.3)] . maternal adverse reactions: vasopressin   may produce tonic uterine contractions that could threaten the continuation of pregnancy . there are no data on the

États-Unis - anglais - NLM (National Library of Medicine)

eugia us llc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. vasopressin injection is contraindicated in patients with known allergy or hypersensitivity to 8-l-arginine vasopressin or chlorobutanol. risk summary there are no available data on vasopressin use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with vasopressin. clinical considerations dose adjustments during pregnancy and the postpartum period: because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin may need to be increased [see dosage and administration (2.2) and clinical pharmacology (12.3)] . maternal adverse reactions: vasopressin  may produce tonic uterine contractions that could threaten the continuation of pregnancy. there are no data on the presence of vasopressin injec